Association between soy and isoflavone consumption, gastrointestinal (GI) cancer risk
the ONA take:
According to a new study published in the European Journal of Nutrition, soy consumption is only associated with a small decrease in gastrointestinal cancer risk, while isoflavone consumption is significantly associated with a reduction in gastrointestinal cancer risk.
For the study, researchers sought to investigate the association between soy and isoflavone consumption and gastrointestinal cancer risk. Isoflavone is an active soy constituent but can be consumed as a dietary supplement.
Researchers identified 22 case-control and 18 cohort studies with a total participation of 633,476 patients and 13,639 cases of gastrointestinal cancer. Of the 40 studies, 10 were used for a subgroup analysis for isoflavone consumption.
Results showed that there was only a small reduction in gastrointestinal cancer risk due to soy intake (combined odds ratio = 0.93; 95% CI: 0.87 - 0.99; P = 0.01).
Particularly, the association was stronger for colon and colorectal cancers. In contrast, the subgroup analysis for isoflavone showed a significant reduction in gastrointestinal cancer risk, especially colorectal cancer risk, due to isoflavone consumption (OR = 0.73; 95% CI: 0.59 - 0.92; P = 0).
Soy consumption is only associated with a small decrease in gastrointestinal cancer risk.
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors
- Directly Informing Patients of Breast Cancer Risk, Options Improves Follow-Up Screening
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- The Integration of Cannabis in Oncologic Care
- CTCs Promising as Biomarker to Identify Lung Cancer Recurrence
- Hypofractionated RT, Conventional RT Comparable in Intermediate-Risk Prostate Cancer
- Social Functioning Scores for Young Cancer Survivors Remain Lower Than Their Peers
- Mortality Rates Highest Among Youngest Oncology Patients, Particularly Minorities
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|